Bioptik Technology (4161) — Capital Reinvestment Ratio
Bioptik Technology (4161) has a Capital Reinvestment Ratio of 0.09x as of December 2025, meaning it reinvests 0% of its operating cash flow (NT$53.21 Million) in capital expenditures (NT$4.94 Million). Check 4161 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Bioptik Technology Capital Reinvestment Ratio (2017–2025)
This chart tracks Bioptik Technology's Capital Reinvestment Ratio across 8 annual periods. For the full cash flow conversion analysis, see Bioptik Technology (4161) cash conversion ratio.
Annual Capital Reinvestment Ratio for Bioptik Technology (2017–2025)
Year-by-year Capital Reinvestment Ratio for Bioptik Technology from 2017 to 2025. See 4161 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.38x | NT$59.99 Million | NT$22.80 Million | ▲ +289.4% |
| 2024 | 0.10x | NT$158.82 Million | NT$15.51 Million | ▼ -35.2% |
| 2023 | 0.15x | NT$205.95 Million | NT$31.04 Million | ▼ -51.4% |
| 2022 | 0.31x | NT$55.06 Million | NT$17.08 Million | ▼ -84.5% |
| 2020 | 2.01x | NT$6.57 Million | NT$13.18 Million | ▲ +200.0% |
| 2019 | 0.67x | NT$41.03 Million | NT$27.42 Million | ▼ -45.1% |
| 2018 | 1.22x | NT$41.83 Million | NT$50.96 Million | ▼ -78.6% |
| 2017 | 5.69x | NT$11.02 Million | NT$62.72 Million | — |